Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites

Hepatology

Volumn 41, Issue 3, 2005, Pages 579-587

  Clària, Joan ^a   Kent, Jeffrey D ^d   López Parra, Marta ^a   Escolar, Ginés ^a   Ruiz del Arbol, Luís ^b   Ginès, Pere ^a   Jiménez, Wladimiro ^a   Vucelic, Boris ^c   Arroyo, Vicente ^a,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c KBC Zagreb   (Croatia)

^d PFIZER INC   (United States)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; FUROSEMIDE; NAPROXEN; PLACEBO; PROSTAGLANDIN E2; SODIUM; THROMBOXANE B2;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RESPONSE; ESOPHAGUS VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; THROMBOCYTE; THROMBOCYTE AGGREGATION; UREMIA; URINE VOLUME;

ASCITES; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NAPROXEN; PLATELET AGGREGATION; PYRAZOLES; RENIN; SULFONAMIDES;

EID: 14244261238     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20595     Document Type: Article

References (45)

1. 1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979;77:215-222.
2. Zipser R, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895-900.
3. 2 in cirrhosis: relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983;13:271-278.
4. Mirouze D, Zipser RD, Reynolds TD. Effects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. HEPATOLOGY 1983;3:50-55.
5. Quintero E, Gines P, Arroyo V, Rimola A, Camps J, Gaya J, et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986;42:298-303.
6. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci 1987;294:168-174.
7. Arroyo V, Ginés P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: an overview with emphasis on pathogenesis. Am J Med 1986;81:104-122.
8. Clària J, Arroyo V. Prostaglandins and other cyclooxygenase- dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins Other Lipid Mediat 2003;72:19-33.
9. Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984;26:72-80.
10. Planas R, Arroyo V, Rimola A, Pérer-Ayuso RM, Rodés J. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983;84;247-522.
11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-235.
12. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A 1992;89:3917-3921.
13. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
14. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160.
15. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002;68-69:165-175.
16. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563-7567.
17. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-12017.
18. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998;95:13313-13318.
19. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-3232.
20. FitrGerald G, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442.
21. Bosch-Marcé M, Clària J, Titos E, Masferrer JL, Altuna R, Poo JL, et al. Selective inhibition of cyclooxygenase-2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999;116:1167-1175.
22. Lòpez-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Koki A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002;135:891-900.
23. Mattix HJ, Badr KF. Arachidonic acid metabolites and the kidney. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia: Saunders, 2000:756-792.
24. Solà J, Camps J, Arroyo V, Guarner F, Gaya J, Rivera F, et al. Longitudinal study of renal prostaglandin excretion in cirrhotic rats: relationship with the renin-aldosterone system. Clin Sci 1988;75:263-269.
25. 2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol 1990;259:F318-F325.
26. 2. Am J Physiol 1984;247:F555-F561.
27. Guevara M, Abecasis R, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. Scand J Gastroentetol 2004;39:385-386.
28. Leehey DJ, Uckerman MT, Rahman MA. Role of prostaglandins and thromboxane in the control of renal hemodynamics in experimental liver cirrhosis. J Lab Clin Med 1989;113:309-315.
29. Ros J, Clària J, Jiménez W, Bosch-Marcé M, Angeli P, Arroyo V, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. HEPATOLOGY 1995;22:915-920.
30. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23:164-176.
31. Whelton A, Schulman G, Wallemark C, Drawer EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-1470.
32. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277.
33. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984;27:291-296.
34. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
35. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983;71:676-688.
36. Wilson TW. Responses to furosemide in normotensive and hypertensive subjects. Clin Pharmacol Ther 1983;34:590-595.
37. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
38. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Int Med 2003;253:643-652.
39. 4: impact of aspirin therapy. Circulation 1992;86:56-63.
40. Engström K, Wallin R, Saldeen T. Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. Prostaglandins Leukot Essent Fatty Acids 2001;64:291-297.
41. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003;7:401-413.
42. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-158.
43. McCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and fulminant hepatic failure. Lancet 1999;353:40-41.
44. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001;77:548-550.
45. Alegria P, Lebre L, Chagas C. Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 2002;137:75.